Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color

Atopic dermatitis is a chronic disease that disproportionately impacts communities of color
Dupixent achieved 75% or greater improvement in overall disease severity, the primary endpoint, in more than three-quarters of treated patients
Patients experienced substantial reductions in hyperpigmentation, dry skin and itch from baseline
Results support commitment to enhance clinical understanding of chronic diseases in communities of color
TARRYTOWN, N.Y. and PARIS, June 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today presented results from the DISCOVER Phase 4, single-arm, open-label trial assessing Dupixent® (dupilumab) in adults and adolescents with moderate-to-severe atopic dermatitis with skin of color. These are the first clinical trial results for Dupixent in a large population of patients with darker skin tones. The results, along with the Dupixent Phase 3 trials, demonstrated patients taking Dupixent experienced improvements in signs and symptoms of atopic dermatitis from baseline across many skin tones. The data were shared in an oral presentation at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.
'Atopic dermatitis, a chronic disease with underlying type 2 inflammation, has a high prevalence and quality of life impact on patients with skin of color. Unique clinical features like darker patches of hyperpigmentation versus redness typically seen on lighter skin may lead to less accurate diagnoses and underestimation of disease severity,' said Andrew Alexis, M.D., M.P.H., Professor of Clinical Dermatology at Weill Cornell Medicine. 'The results from the DISCOVER trial showed that Dupixent patients with atopic dermatitis and darker skin not only experienced reduced disease severity and itch but also saw improvements in areas of particular concern including dyspigmentation and dry skin. These data deepen the clinical understanding of atopic dermatitis within this underserved population, including use of newly validated scales.'
In the trial, 120 patients with atopic dermatitis and skin of color (82% Black, 11% Asian, 2% American Indian/Alaska Native, 5% Arab, Central American or other) were treated with Dupixent every two weeks using a weight-based dosing regimen. At 24 weeks:
The safety results in the DISCOVER trial were generally consistent with the known safety profile of Dupixent in its approved dermatological indications. The overall rate of adverse events (AEs; n=124) in the DISCOVER trial was 42%, with the most common (≥2%) AEs being headache (3%), upper respiratory tract infection (2%), eczema (2%), conjunctivitis (3%) and allergic conjunctivitis (2%).
About Atopic Dermatitis in Skin of Color
Atopic dermatitis is a chronic skin disease with underlying type 2 inflammation that causes intense, persistent itch and skin lesions that cover much of the body, resulting in skin dryness, cracking, pain, crusting and oozing. In patients with skin of color, the type and location of the lesions can vary, and they are more likely to have hardened skin lesions and severe skin dryness, itch, dyspigmentation and greater disease severity than those with lighter skin. Additionally, redness that is observed on lighter skin typically appears as darkened, grey or violet on darker skin tones. Because the disease presents differently in people with skin of color, it can be misdiagnosed or the severity underestimated, which can contribute to higher levels of healthcare resource utilization.
About the DISCOVER Clinical Trial
The DISCOVER Phase 4 open-label, single-arm trial evaluated the efficacy and safety of Dupixent in adults and adolescents aged 12 years and older with moderate-to-severe atopic dermatitis and skin of color, as defined by Fitzpatrick skin types IV-VI (those with high melanin; light brown to black). During the 24-week treatment period, all patients in the trial received Dupixent monotherapy every two weeks based on weight after a loading dose: patients weighing ≥30 to <60 kg received 200 mg and patients weighing ≥60 kg received 300 mg.
The primary endpoint assessed the proportion of patients who achieved at least 75% improvement on the Eczema Area and Severity Index (EASI-75) at 24 weeks. Secondary endpoints included the proportion of patients who achieved ≥4-point improvement on the Peak-Pruritus Numerical Rating Scale (PP-NRS) at 24 weeks. Additional endpoints included pigmentary changes on the clinician-reported Post-Inflammatory Hyperpigmentation Severity Scale (PHSS; scale: 0-8) and skin dryness on the newly developed patient-reported Xerosis NRS (X-AD; scale: 0-10) at 24 weeks.
About Dupixent
Dupixent, which was invented using Regeneron's proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases.
Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU) and chronic obstructive pulmonary disease (COPD) in different age populations. More than 1,000,000 patients are being treated with Dupixent globally.1
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite ® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent® (dupilumab), Libtayo® (cemiplimab-rwlc), Praluent® (alirocumab), Kevzara® (sarilumab), Evkeeza® (evinacumab-dgnb), Inmazeb® (atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz® (pozelimab-bbfg). In addition, REGEN-COV® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024.
Dupilumab Development Program
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin, bullous pemphigoid, and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority.
U.S. INDICATIONS
DUPIXENT is a prescription medicine used:
DUPIXENT is not used to relieve sudden breathing problems and will not replace an inhaled rescue medicine.
DUPIXENT is not used to treat any other forms of hives (urticaria).
IMPORTANT SAFETY INFORMATION
Do not use if you are allergic to dupilumab or to any of the ingredients in DUPIXENT®.
Before using DUPIXENT, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Especially tell your healthcare provider if you are taking oral, topical, or inhaled corticosteroid medicines; have asthma and use an asthma medicine; or have atopic dermatitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease, or chronic spontaneous urticaria, and also have asthma. Do not change or stop your other medicines, including corticosteroid medicine or other asthma medicine, without talking to your healthcare provider. This may cause other symptoms that were controlled by those medicines to come back.
DUPIXENT can cause serious side effects, including:
The most common side effects include:
Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of DUPIXENT. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Use DUPIXENT exactly as prescribed by your healthcare provider. It's an injection given under the skin (subcutaneous injection). Your healthcare provider will decide if you or your caregiver can inject DUPIXENT. Do not try to prepare and inject DUPIXENT until you or your caregiver have been trained by your healthcare provider. In children 12 years of age and older, it's recommended DUPIXENT be administered by or under supervision of an adult. In children 6 months to less than 12 years of age, DUPIXENT should be given by a caregiver.
Please see accompanying full Prescribing Information including Patient Information.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
Regeneron Forward-Looking Statements and Use of Digital Media
This press release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. ('Regeneron' or the 'Company'), and actual events or results may differ materially from these forward-looking statements. Words such as 'anticipate,' 'expect,' 'intend,' 'plan,' 'believe,' 'seek,' 'estimate,' variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Products') and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, 'Regeneron's Product Candidates') and research and clinical programs now underway or planned, including without limitation Dupixent®(dupilumab); uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary), including the studies discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial launch of Regeneron's Product Candidates and new indications for Regeneron's Products, such as Dupixent for the treatment of chronic pruritus of unknown origin, bullous pemphigoid, lichen simplex chronicus, and other potential indications; the ability of Regeneron's collaborators, licensees, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; the ability of Regeneron to manage supply chains for multiple products and product candidates and risks associated with tariffs and other trade restrictions; safety issues resulting from the administration of Regeneron's Products (such as Dupixent) and Regeneron's Product Candidates in patients, including serious complications or side effects in connection with the use of Regeneron's Products and Regeneron's Product Candidates in clinical trials; determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement or copay assistance for Regeneron's Products from third-party payors and other third parties, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payors and other third parties and new policies and procedures adopted by such payors and other third parties; changes in laws, regulations, and policies affecting the healthcare industry; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates (including biosimilar versions of Regeneron's Products); the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics on Regeneron's business; and risks associated with litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA®(aflibercept) Injection), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2024 and its Form 10-Q for the quarterly period ended March 31, 2025. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.
Regeneron uses its media and investor relations website and social media outlets to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Regeneron is routinely posted and is accessible on Regeneron's media and investor relations website (https://investor.regeneron.com) and its LinkedIn page (https://www.linkedin.com/company/regeneron-pharmaceuticals).
Sanofi Disclaimers or Forward-Looking Statements
This media update contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates regarding the marketing and other potential of the product, or regarding potential future revenues from the product. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans', and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, unexpected regulatory actions or delays, or government regulation generally, that could affect the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.
All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center .
1 Data on File

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Fox News

24 minutes ago

• Fox News

Top Trump health official slams Democrats for 'misleading' claims about Medicaid reform

FIRST ON FOX: A top Trump White House official is looking to undercut Senate Democrats' talking points on Medicaid, arguing that the GOP's plan to reform the healthcare program would benefit rural hospitals, not harm them. Centers for Medicare and Medicaid Services Administrator Dr. Mehmet Oz told Fox News Digital that "special interests are pushing misleading talking points to try and stop the most ambitious healthcare reforms ever." Oz's sentiment comes as Senate Majority Leader John Thune, R-S.D., and Senate Republicans sprint to finish their work on President Donald Trump's "big, beautiful bill" ahead of a self-imposed July 4 deadline. Part of the bill from the Senate Finance Committee aims to make good on the GOP's promise to root out waste, fraud and abuse within the widely used healthcare program by including work requirements and booting illegal immigrants from benefit rolls, among other measures. Tweaks to the Medicaid provider tax rate have ruffled feathers on both sides of the aisle. Indeed, Senate Minority Leader Chuck Schumer, D-N.Y. and Sens. Ron Wyden, D-Ore., and Jeff Merkley, D-Ore., sent a letter to Trump and the top congressional Republicans last week warning that changes to the Medicaid provider tax rate would harm over 300 rural hospitals. And a cohort of Senate Republicans were furious with the change after the bill dropped last week. But Oz contended that "only 5%" of inpatient Medicaid spending happens in rural communities, and that the mammoth bill "instead targets abuses overwhelmingly utilized by large hospitals with well-connected lobbyists." "We are committed to preserving and improving access to care in rural communities with a transformative approach that bolsters advanced technology, invests in infrastructure, and supports workforce — rather than propping up a system that mostly benefits wealthier urban areas," Oz said. Schumer's letter included data from a study recently conducted by the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at his behest. He warned that if the bill is passed as is, millions of people would be kicked off of their healthcare coverage, and "rural hospitals will not get paid for the services they are required by law to provide to patients." Fox News Digital reached out to Schumer, Wyden and Merkley for comment. However, another report from the Trump-aligned Paragon Health Institute argued similarly to Oz that special interest groups and healthcare lobbyists were "flooding the airwaves with claims" that Republicans' changes to Medicaid would shutter rural hospitals. For example, they argued that a recent report from the Center for American Progress warned that over 200 rural hospitals would be at risk of closure, but that the findings were based on changes to the federal medical assistance percentage, or the amount of Medicaid costs paid for by the federal government. Changes to that percentage were mulled by congressional Republicans but were not included in the "big, beautiful bill." Still, the changes to the Medicaid provider tax rate, which were a stark departure from the House GOP's version of the bill, angered the Republicans who have warned not to make revisions to the healthcare program that could shut down rural hospitals and boot working Americans from their benefits. The Senate Finance Committee went further than the House's freeze of the provider tax rate, or the amount that state Medicaid programs pay to healthcare providers on behalf of Medicaid beneficiaries, for non-Affordable Care Act expansion states, and included a provision that lowers the rate in expansion states annually until it hits 3.5%. However, Sen. Susan Collins, R-Maine, is working on a possible change to the bill that would create a provider relief fund that could sate her and other Republicans' concerns about the change to the provider tax rate.

Health Line

29 minutes ago

• Health Line

What Are Intramuscular Injections?

An intramuscular injection is a technique for delivering medication deep into the muscles. This allows the medication to absorb quickly into the bloodstream. You may have received an intramuscular injection at a doctor's office the last time you got a vaccine, like the flu shot. In some cases, a person may also self-administer an intramuscular injection. For example, certain drugs that treat multiple sclerosis or rheumatoid arthritis may require self-injection. What are intramuscular injections used for? Intramuscular injections are a common practice in modern medicine. They're used to deliver drugs and vaccines. Several drugs and almost all injectable vaccines are delivered this way. Intramuscular injections are used when other types of delivery methods are not recommended. These include: oral (swallowed into the stomach) intravenous (injected into the vein) subcutaneous (injected into the fatty tissue just under the layer of skin) Intramuscular injections may sometimes be used instead of intravenous injections because some drugs are irritating to veins or because a suitable vein cannot be located. However, not all intravenous medications can be administered intramuscularly. They may be used instead of oral delivery because some drugs are destroyed by the digestive system when you swallow them. Intramuscular injections are absorbed faster than subcutaneous injections. This is because muscle tissue has a greater blood supply than the tissue just under your skin. Muscle tissue can also hold a larger volume of medication than subcutaneous tissue. Intramuscular injection sites Intramuscular injections are often given in the following areas: Deltoid muscle of the arm The deltoid muscle is the site most typically used for vaccines. However, this site is not common for self-injection because its small muscle mass limits the volume of medication that can be injected — typically no more than 1 milliliter. It's also challenging to use this site for self-injection. A caregiver, friend, or family member can assist with injections into this muscle. To locate this site, feel for the bone (acromion process) located at the top of your upper arm. The correct area to give the injection is two finger widths below the acromion process. At the bottom of the two fingers will be an upside-down triangle. Give the injection in the center of the triangle. Vastus lateralis muscle of the thigh The thigh may be used when the other sites are not available or if you need to administer the medication on your own. Divide the upper thigh into three equal parts. Locate the middle of these three sections. The injection should go into the outer top portion of this section. Ventrogluteal muscle of the hip The ventrogluteal muscle is the safest site for adults and children older than 7 months. It's deep and not close to any major blood vessels or nerves. However, this site is difficult for self-injection and may require the help of a friend, family member, or caregiver. Place the heel of your hand on the hip of the person receiving the injection, with your fingers pointing toward their head. Position your fingers so your thumb points toward their groin, and you feel the pelvis under your pinky finger. Spread your index and middle fingers in a slight V shape, and inject the needle into the middle of that V. Dorsogluteal muscles of the buttocks For many years, healthcare professionals most commonly selected the dorsogluteal muscle of the buttocks. However, due to the potential for injury to the sciatic nerve, the ventrogluteal muscle is most often used instead. This site in the dorsogluteal muscle is difficult to use for self-injection and is not recommended. You should not use an injection site that has evidence of infection or injury. If you'll be giving the injection more than once, rotate the injection sites to avoid injury or discomfort to the muscles. How to administer an intramuscular injection Anyone who administers intramuscular injections should receive training and education on proper injection techniques. The needle size and injection site will depend on many factors. These include the age and size of the person receiving the medication, and the volume and type of medication. Your doctor or pharmacist will give you specific guidelines about which needle and syringe are appropriate to administer your medication. The needle should be long enough to reach the muscle without penetrating the nerves and blood vessels underneath. Generally, needles should be 1 inch to 1.5 inches for an adult and will be smaller for a child. They'll be 22-gauge to 25-gauge thick, noted as 22g on the packaging. Follow these steps for a safe intramuscular injection: 1. Wash your hands Wash your hands with soap and warm water to prevent potential infection. Be sure to thoroughly scrub between your fingers, on the backs of your hands, and under your fingernails. The Centers for Disease Control and Prevention (CDC) recommends lathering for 20 seconds, which is the time it takes to sing the 'Happy Birthday' song twice. 2. Gather all the needed supplies Assemble the following supplies: needle and syringe with medication alcohol pads gauze puncture-resistant container to discard the used needles and syringe (typically a red, plastic sharps container) bandages 3. Locate the injection site To isolate the muscle and target where you'll place the injection, spread the skin at the injection site between two fingers. The person receiving the injection should get into a comfortable position that allows easy access to the location and keeps the muscles relaxed. 4. Clean the injection site Clean the site selected for injection with an alcohol swab and allow the skin to air dry. 5. Prepare the syringe with medication Remove the cap. If the vial or pen is multidose, note when the vial was first opened. The rubber stopper should be cleaned with an alcohol swab. Draw air into the syringe. Draw back the plunger to fill the syringe with air up to the dose that you'll be injecting. This is done because the vial is a vacuum, and you need to add an equal amount of air to regulate the pressure. This also makes it easier to draw the medication into the syringe. If you forget this step, you can still get the medication out of the vial. Insert air into the vial. Remove the cap from the needle and push the needle through the rubber stopper at the top of the vial. Inject all of the air into the vial. Be careful not to touch the needle to keep it clean. Withdraw the medication. Turn the vial and syringe upside down so the needle points upward, and pull back on the plunger to withdraw the correct amount of medication. Remove air bubbles. Tap the syringe to push any bubbles to the top and gently depress the plunger to push the air bubbles out. 6. Self-inject with a syringe Hold the needle like a dart and insert it into the muscle at a 90-degree angle. You should insert the needle in a quick but controlled manner. Do not push the plunger in. 7. Inject the medication Push the plunger slowly to inject the medication into the muscle. 8. Remove the needle Withdraw the needle quickly and discard it into a puncture-resistant sharps container. Do not put the cap back on the needle. A sharps container is a red container that you can purchase at any pharmacy. It collects medical waste, such as needles and syringes. You should not put these materials into the regular garbage, as needles can be hazardous to anyone who handles the trash. 9. Apply pressure to the injection site Use a piece of gauze to apply light pressure to the injection site. You can even massage the area to help the medication be absorbed into the muscle. It's routine to see slight bleeding. Use a bandage if necessary. Tips for an easier injection To minimize possible discomfort before your injection: Apply ice or an over-the-counter topical numbing cream to the injection site before cleaning it with the alcohol pad. Allow the alcohol to dry completely before the injection. Otherwise, it might cause stinging. Warm the vial of medication by rubbing it between your hands before drawing the medication into the syringe. Have someone you trust give you the injection. Some people find it difficult to inject themselves. What are the complications of intramuscular injections? It's typical to experience some discomfort after an intramuscular injection. However, certain symptoms may be signs of a more serious complication. Call your doctor or healthcare professional right away if you experience: You may have some anxiety about performing or receiving an injection, especially an intramuscular injection, due to the long needle. Read through the steps several times until you feel comfortable with the procedure, and take your time. You can ask your doctor or pharmacist to go through the procedure with you beforehand. They're more than willing to help you understand how to perform a safe, proper injection.

CNN

31 minutes ago

• CNN

CDC vaccine advisers to vote on thimerosal in flu shots at first meeting of new panel

Vaccines Federal agencies Respiratory viruses Children's healthFacebookTweetLink Follow A newly posted agenda for next week's meeting of the just-appointed group of outside vaccine advisers to the US Centers for Disease Control and Prevention includes a discussion and vote on thimerosal in flu vaccines, a preservative tied to debunked claims from decades ago of links to autism. The meeting, scheduled to start June 25 and run for two days, is the first for a newly installed group of eight Advisory Committee on Immunization Practices members. US Health and Human Services Secretary Robert F. Kennedy Jr. dismissed the previous group of 17 experts last week, claiming that they had conflicts of interest. A number of the new panelists, though, have raised concerns from the public health world for their positions on vaccines, including serving as expert witnesses in lawsuits against vaccine makers and suggesting without evidence that Covid-19 vaccines kill young people and should immediately be removed from the market. It's not clear what the discussion and vote at next week's meeting on thimerosal in flu vaccines will entail, and the presenter of the information at the meeting is listed on the agenda as 'TBD.' A spokesperson for HHS directed questions about the nature of the discussion and vote back to the posted agenda. Thimerosal is a mercury-based compound used to prevent bacteria and fungus from growing in vaccines, and the CDC says data from multiple studies 'show no evidence of harm caused by the low doses of thimerosal in vaccines.' Nonetheless, the use of thimerosal in vaccines has declined significantly since the US Food and Drug Administration in 1999 asked vaccine manufacturers to detail plans to remove it; the FDA now says 'all vaccines routinely recommended for children 6 years of age and younger in the U.S. are available in formulations that do not contain thimerosal.' The preservative is still used in some multidose vials of seasonal flu vaccines. Since thimerosal was largely removed from pediatric vaccines, autism rates have continued to rise, which the CDC notes 'is the opposite of what would be expected if thimerosal caused autism.' Thimerosal has long been a focus of Kennedy, who published a book in 2014 called 'Thimerosal: Let the Science Speak,' referring to it as 'mercury, a known neurotoxin.' The CDC points out, however, that there are two kinds of mercury – methylmercury and ethylmercury – and high levels of the first can be toxic to people. Thimerosal contains ethylmercury, the agency says, 'which is cleared from the human body more quickly than methylmercury, and is therefore less likely to cause any harm.' The fact that thimerosal is now on the agenda of Kennedy's newly appointed vaccine advisers suggests they may publicly claim, against evidence, that the preservative is dangerous, said Dr. Paul Offit, a vaccine scientist at Children's Hospital of Philadelphia and an outside vaccine adviser to the FDA. 'All that's going to do is make it so that those vaccines will become less available and more expensive,' Offit told CNN. 'It certainly won't make them safer.' Offit pointed out that reformulating those vaccines couldn't be done quickly by manufacturers, so it would 'most likely just lead to vaccine shortages and make the vaccines more expensive.' Also new to the agenda is a discussion and proposed recommendations for the measles, mump, rubella and varicella (or chickenpox) vaccine for children under 5. It's not clear what the nature of that discussion will be either, and its presenters are also listed as 'TBD.' The combination vaccine, known as MMRV, has been approved in the US as ProQuad since 2005, and the CDC notes that while the combination vaccine has one fewer injection than the individual shots, it's associated with a higher risk for fever and febrile seizures five to 12 days after the first dose among children between 1 and 2 years old. Administering the varicella vaccine separately from the MMR vaccine avoids this increased risk, which the CDC points out is 'very low for both options.' Although it's not clear whether that will be the focus of the presentation and recommendations, Offit noted that vaccine advisers have already had that discussion, so 'I'm not sure what's going to be added here.' The meeting had been scheduled to take place over three days, according to a June 9 posting in the Federal Register, and now has been shortened to two. It still includes votes on RSV immunization for pregnant women and children and in the Vaccines for Children program, as well as planned discussions on Covid-19, chikungunya and anthrax vaccines, but the topic list has been significantly slimmed down. No longer included are discussions on cytomegalovirus vaccine, human papillomavirus (HPV) vaccine, Lyme disease vaccine, meningococcal vaccine and pneumococcal vaccines. At an internal meeting Tuesday among CDC employees, a member of leadership told staffers that some agenda items for the upcoming ACIP meeting might not be included because they were still bringing new members up to speed, according to a CDC employee who requested anonymity for fear of reprisal. The employee called that reasoning 'a transparent lie; they wouldn't have had to bring all these new people up to speed if they hadn't fired the old ones.' The agenda also includes a number of 'TBD' listings for presenters, including on the safety of Covid-19 vaccines and RSV immunizations. At previous meetings, those presentations on Covid-19 have been made by Dr. Fiona Havers and Dr. Lakshmi Panagiotakopoulos, who both resigned in the past few weeks, citing concerns about changes to the CDC's vaccine processes under Kennedy. 'My career in public health and vaccinology started with a deep-seated desire to help the most vulnerable members of our population,' Panagiotakopoulos wrote in an email to former ACIP members, obtained by CNN, 'and that is not something I am able to continue doing in this role.'